Diflucan (fluconazole): Drug Safety Communication – Long-term, High-dose Use During Pregnancy May Be Associated With Birth Defects

Audience: OBGYN, Pharmacy, Infectious Disease ISSUE: FDA is informing the public that treatment with chronic, high doses (400-800mg/day) of Diflucan (fluconazole) during the first trimester of pregnancy may be associated with a rare and distinct set…

Related posts:

1. Zyvox (linezolid): Drug Safety Communication – Serious CNS Reactions Possible When Given to Patients Taking Certain Psychiatric Medications Audience: Infectious Disease, Psychiatry, Family Practice ISSUE: FDA has received...
2. Valproate Products: Drug Safety Communication – Risk of Impaired Cognitive Development in Children Exposed In Utero (During Pregnancy) Audience: OBGYN, Neurology, Psychiatry Including valproate sodium (Depacon), divalproex sodium...
3. Angiotensin Receptor Blockers (ARBs): Drug Safety Communication – Drug Safety Review Completed Audience: Cardiology, Oncology, Family Practice [UPDATED 06/02/2011] FDA’s meta-analysis of...
4. Proton Pump Inhibitor drugs (PPIs): Drug Safety Communication – Low Magnesium Levels Can Be Associated With Long-Term Use Audience: Consumer, Gastroenterology, Family Practice Prescription PPIs include Nexium (esomeprazole...